Bright Minds Biosciences Inc. — FY2023 Form 20-F
Reporting period: Fiscal year ended September 30, 2023, not a standalone 2023 fourth-quarter report. Financial statements are prepared under IFRS and presented in Canadian dollars (C$), unless noted. The company is an early-stage biotechnology developer of serotonergic therapeutics, with programs focused on CNS disorders including epilepsy and neuropsychiatric conditions. It has no product revenue.
Financial performance and position
| Metric | FY2023 / September 30, 2023 | Prior comparable period |
|---|---|---|
| Revenue | Nil | Nil |
| Net loss | C$7.37 million | FY2022: C$14.96 million reported in most sections; the audited statements show C$14.963 million |
| Research and development expense | C$5.00 million | FY2022: C$12.18 million |
| Net cash used in operating activities | C$7.02 million | FY2022: C$13.59 million |
| Cash and cash equivalents | C$6.75 million | September 30, 2022: C$11.63 million |
| Working capital | Surplus of C$6.53 million | September 30, 2022: surplus of C$10.48 million |
| Total liabilities | C$0.28 million, including C$0.07 million current lease liability | September 30, 2022: C$1.54 million |
| Basic and diluted loss per share | C$1.98 loss | FY2022: C$6.06 loss |
No meaningful revenue or operating margin comparison is available because the company has not generated revenue. Its FY2023 loss narrowed as R&D spending and several operating expense categories fell; management attributed the R&D decline to completion of certain activities. Share-based compensation was C$1.15 million, primarily recorded in directors’ compensation. Australian R&D tax credits reduced R&D expense by C$0.35 million.
FY2023 financing activities provided C$2.19 million, mainly from a private placement and pre-funded warrants, partly offset by lease principal and share issuance costs. The company reported no long-term debt. Lease commitments were the principal disclosed contractual obligation; the contractual-obligations table reports a total of C$90,523, although its listed lease obligation is C$80,509.
Material changes and business developments
- Bright Minds completed its first Phase 1 trial of lead candidate BMB-101 in July 2023. The filing reports that it was safe and well tolerated in healthy subjects; maximum tolerated doses were 180 mg/70 kg in the single-ascending-dose study and 150 mg/70 kg twice daily in the multiple-ascending-dose study. Plasma half-life was 5–7 hours, and prolactin and qEEG changes were reported as consistent with central target engagement.
- R&D expense decreased to C$5.00 million from C$12.18 million, including lower spending across the disclosed 5-HT2A, 5-HT2C and 5-HT2C/A portfolios. The filing describes preclinical work across epilepsy, opioid use disorder, binge eating, depression and pain; these are preclinical findings, not demonstrated clinical efficacy.
- On July 14, 2023, the company consolidated its shares on a 1-for-5 basis. Financial-statement share figures are presented retrospectively on the post-consolidation basis.
- At September 30, 2023, 3,772,072 common shares were outstanding. Subsequent to year-end, the company issued 661,765 units for C$900,000 gross proceeds and an officer exercised 30,000 RSUs. The cover reports 4,463,837 shares outstanding at the period covered; this appears consistent with the subsequent share and RSU issuances, rather than the year-end balance.
Outlook, risks and other disclosures
- Management expects continued losses and negative operating cash flow in FY2024. It stated that existing funds were expected to support operations for the next 12 months, while also anticipating further equity financing. The filing cautions that financing may not be available on acceptable terms and that operations could be curtailed or cease if funding is insufficient.
- The financial statements are prepared on a going-concern basis. The company had a C$31.55 million accumulated deficit at year-end and depends on future financing and successful development; there is no assurance it will achieve profitability or generate revenue.
- Key risks include clinical and regulatory failure or delay, adverse safety findings, difficulty enrolling trial participants, uncertain intellectual-property protection, competition, foreign-exchange exposure, dilution and limited trading liquidity. A 10% change in the U.S. or Australian dollar against the Canadian dollar was estimated to affect comprehensive loss by approximately C$132,000.
- The company licenses university-owned patent rights under an agreement that includes royalties, annual minimums, milestone payments and reimbursement of patent costs. No material litigation was reported.
- Management concluded disclosure controls and internal control over financial reporting were effective as of September 30, 2023. The auditor issued an unmodified opinion on the IFRS financial statements, but did not attest to internal control effectiveness. No critical audit matters were identified.
Important facts for investors to verify
- Reconcile the FY2022 net-loss figure: the MD&A and cash-flow/equity statements report C$14,964,941, while the audited statement of comprehensive loss reports C$14,962,941.
- Confirm the year-end versus post-year-end share counts and the treatment and timing of the December 2023 unit issuance and RSU exercise.
- Assess cash runway against actual spending, the timing and cost of planned clinical development, and the company’s stated need for additional financing.
- Review final clinical-trial data and regulatory plans for BMB-101; the Phase 1 results do not establish efficacy in patients or predict later-stage outcomes.
- Check the contractual-obligations table’s C$90,523 total against its C$80,509 listed lease obligation, and review the license agreement’s future milestone, royalty and minimum-payment terms.